Investing in pharmaceutical stocks has been a hot topic this year, with some companies outperforming others in the industry. Eli Lilly and Co. (LLY) has seen a significant increase of 63% this year, surpassing the S & P 500 Pharmaceuticals index by over 40%. While LLY has been a strong performer, other high-profile stocks like Bristol-Myers Squibb Co. (BMY), Johnson & Johnson (JNJ), and Pfizer Inc. (PFE) have not fared as well.
However, there are signs that these lagging pharmaceutical stocks may be ready for a turnaround. Analysis of their monthly charts reveals long-term downside exhaustion, with oversold upturns in their monthly stochastic oscillators and a loss of long-term downside momentum in their monthly MACDs. This indicates that their cyclical downtrends may be coming to an end, potentially signaling a lasting turnaround.
When comparing LLY to these lagging pharmaceutical stocks, such as PFE, a steep uptrend is still in place indicating outperformance. However, there are signs that LLY may be losing its leadership stronghold, potentially paving the way for better relative performance from PFE and other laggards in the pharmaceutical space in the coming year.
At Extreme Investor Network, we believe in providing valuable insights and analysis to help investors make informed decisions. Our team of experts closely monitors market trends and opportunities to ensure our members stay ahead of the curve. Join us today to access exclusive research and strategies to maximize your investment potential. Remember, before making any financial decisions, seek advice from your own financial advisor.
Invest with confidence. Join Extreme Investor Network today.